2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.045
-0.065 (-5.86%)
At close: Mar 27, 2026
Market Cap26.23M +163.2%
Revenue (ttm)1.98M -49.7%
Net Income-26.35M
EPS-1.50
Shares Out25.10M
PE Ration/a
Forward PEn/a
Dividend0.08 (7.57%)
Ex-Dividend DateJun 27, 2025
Volume36,485
Average Volume45,028
Open1.075
Previous Close1.110
Day's Range1.045 - 1.075
52-Week Range0.330 - 5.520
Beta2.74
RSI35.04
Earnings DateMay 21, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. The company’s principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient’s tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements